Study | Study period | Country | Age | Number of participants | Stage | Grade | HRT Type | HRT recency | CRC death/HRT user | All-cause death /HRT user | Mean follow-up year |
---|---|---|---|---|---|---|---|---|---|---|---|
Prospective cohort | |||||||||||
Arem et al. (2015) [13] | 1995–2011 | USA | 50–71 | 2053 | 30.5% localized, 31.3% regional or distant, 38.2% unknown | 12.0% well-differentiated, 57.5% moderate-differentiated, 0.9% undifferentiated, 29,6% unknown | E, E + P | Current, former | Current (98/670), former (36/201) | Current (214/670), former (87/201) | 7.7 |
Chan et al. (2006) [14] | 1976–2004 | USA | 62.2–65.7a | 834 | 22.3% stage I, 26.1% stage II, 25.5% stage III, 15.6% stage IV, 10.5% unknown | 22.3% stage I, 26.1% stage II, 25.5% stage III, 15.6% stage IV, 10.5% unknown | E, E + P | Current, former | Current (64/235), former (83/229) | Current (87/235), former (103/229) | 5–10 |
Mandelson et al. (2003) [15] | 1980–1998 | USA | 50–79 | 699 | NR | NR | E, E + P | Current | Current (18/103) | Current (37/103) | 5.33 |
Slattery et al. (1999) [16] | 1991–1998 | USA | 55–79 | 801 | 35.4% local, 53.2% regional, 11.4% distant | NR | E, E + P | Current to stop less than 5 years | Current to stop less than 5 years (NR/186) | Current to stop less than 5 years (46/186) | 4.0 |
Retrospective cohort | |||||||||||
Ji et al. (2018) [17] | 2006–2015 | Sweden | 45–69 | 5626 | 23.7% stage I, 27.8% stage II, 36.2% stage III, 12.3% stage IV | NR | E, E + P | Current | Current (NR/1109) | Current (246/1109) | 5.4 |
Study | Variables adjusted | Exposure assessment | Mortality ascertainmentb | ||||||||
Prospective cohort | |||||||||||
Arem et al. (2015) [13] | Years from questionnaire to diagnosis, BMI, marital status, smoking status, diabetes, physical activity, cancer stage, tumor grade, and receipt of chemotherapy, radiation, and surgery | Questionnaire | Social Security Administration Death Master File and the National Death Index Plus | ||||||||
Chan et al. (2006) [14] | Age at diagnosis, year of diagnosis, cancer site (colon, rectum, or unknown), BMI, aspirin use at diagnosis, smoking status, postdiagnosis physical activity, cancer stage, tumor grade, and receipt of chemotherapy | Questionnaire | National Death Index and physician reviewer | ||||||||
Mandelson et al. (2003) [15] | Age at diagnosis; year of diagnosis; and cancer stage | Group Health Cooperative computerized pharmacy database | Western Washington SEER registry | ||||||||
Slattery et al. (1999) [16] | Age at diagnosis, study center, BMI, and cancer stage | In-person interview | Local tumor registries | ||||||||
Retrospective cohort | |||||||||||
Ji et al. (2018) [17] | Age at diagnosis; year of diagnosis, country of birth (Sweden, European countries and others), highest educational level, family history of CRC, comorbidities with chronic ischemic heart disease, type 2 diabetes, chronic obstructive pulmonary disease and hypertension; and cancer stage | Swedish Prescribed Drug Register | Cause of Death Register |